Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06221072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Name: A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid — clinical trial record (NCT06221072)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorShanghai JMT-Bio Inc.

Started2024-04-05

View on ClinicalTrials.gov ↗

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.

Trial Details

NCT Number	NCT06221072
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
Enrollment	1,360 participants
Start Date	2024-04-05
Primary Completion	2027-05-31 (estimated)
Study Completion	2028-05-31 (estimated)
Updated on ClinicalTrials.gov	2024-01-24